Hanmi Pharmaceutical said Tuesday that Sanofi would begin to conduct phase 3 clinical trials of its new antidiabetic, Efpeglenatide, next Monday.
Efpeglenatide is a glucagon-like peptide-1 (GLP-1) diabetes treatment that extended the injection interval from once a day to a week and to as long as a month.
Hanmi confirmed the clinical trials after Sanofi updated its plans on “Clinical Trials,” a global clinical information site. Under the updated plans, Sanofi will treat 400 patients with type 2 diabetes with Efpeglenatide.
Hanmi 한미약품 had initially licensed out Efpeglenatide in 2015, along with two other diabetes treatment, LAPS-insulin115 and a combination of Efpeglenatide and LAPS-insulin115, collectively known as the “Quantum Project.” In December last year, however, Sanofi gave back the rights to the insulin combination drug and postponed the clinical trials of Efpeglenatide.
<© Korea Biomedical Review, All rights reserved.>